Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
32298757
DOI
10.1016/j.ejpb.2020.04.005
PII: S0939-6411(20)30098-9
Knihovny.cz E-zdroje
- Klíčová slova
- Abiraterone acetate, Bioavailability, Food effect, Precipitation, Solid dispersion, Spray drying,
- MeSH
- abirateron chemie metabolismus MeSH
- biologická dostupnost MeSH
- interakce mezi potravou a léky fyziologie MeSH
- koncentrace vodíkových iontů MeSH
- krysa rodu Rattus MeSH
- omezení příjmu potravy metabolismus MeSH
- polymery chemie MeSH
- pomocné látky chemie MeSH
- potkani Wistar MeSH
- preklinické hodnocení léčiv MeSH
- terapeutická ekvivalence MeSH
- uvolňování léčiv fyziologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- abirateron MeSH
- polymery MeSH
- pomocné látky MeSH
Abiraterone acetate is a potent drug used for the treatment of metastatic castration resistant prostate cancer. However, currently marketed product containing crystalline abiraterone acetate exhibits strong positive food effect which results in strict dosing regimen. In the present work, a rational approach towards design of novel abiraterone acetate formulations that would allow increased bioavailability on a fasting stomach and thus decreased food effect is presented. Precipitation experiments in biorelevant media were designed to assess pH induced precipitation of the drug and a pool of polymeric excipients was then screened for their potential to inhibit precipitation. The best performing polymeric excipients were subsequently used as carriers for the preparation of amorphous solid dispersions. Two main approaches were followed in order to formulate the drug. The first approach relies on the suppression of precipitation from a supersaturated solution whereas the second one is based on the hypothesis that when the release of the drug is tuned, optimal uptake of the drug can be reached. Optimized formulation prototypes were tested in a rat animal model in an incomplete block, randomized bioequivalence study to assess their relative bioavailability under fasting conditions. We show that both formulation approaches lead to increased bioavailability of abiraterone acetate on a fasting stomach with bioavailability in rats being enhanced up to 250% compared to the original drug product containing crystalline drug.
Department of Analytical Chemistry Faculty of Science Charles University Prague Czech Republic
Citace poskytuje Crossref.org
Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats
Rifampin-Releasing Triple-Layer Cross-Linked Fresh Water Fish Collagen Sponges as Wound Dressings